Who are VaxigripTetra™ by Sanofi, Inc.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FLUAD Quadrivalent, Control Quadrivalent influenza virus vaccine, IL-YANG Quadrivalent Influenza Vaccine, FluLavalTM-VB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaxigriptetra-by-sanofi-inc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

VaxigripTetra™ by Sanofi, Inc. — Competitive Intelligence Brief

VaxigripTetra™ by Sanofi, Inc. (VaxigripTetra™ by Sanofi, Inc.) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated quadrivalent influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated quadrivalent influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

VaxigripTetra™ by Sanofi, Inc. (VaxigripTetra™ by Sanofi, Inc.) — Centers for Disease Control and Prevention. VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
VaxigripTetra™ by Sanofi, Inc. TARGET	VaxigripTetra™ by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Inactivated quadrivalent influenza vaccine
FLUAD Quadrivalent	FLUAD Quadrivalent	Centers for Disease Control and Prevention	marketed	Inactivated quadrivalent influenza vaccine
Control Quadrivalent influenza virus vaccine	Control Quadrivalent influenza virus vaccine	Sinovac Biotech Co., Ltd	phase 3	Inactivated quadrivalent influenza vaccine
IL-YANG Quadrivalent Influenza Vaccine	IL-YANG Quadrivalent Influenza Vaccine	Il-Yang Pharm. Co., Ltd.	phase 3	Inactivated quadrivalent influenza vaccine
FluLavalTM-VB	FluLavalTM-VB	GlaxoSmithKline	phase 3	Inactivated quadrivalent influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated quadrivalent influenza vaccine class)

Centers for Disease Control and Prevention · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Il-Yang Pharm. Co., Ltd. · 1 drug in this class
Sinovac Biotech Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VaxigripTetra™ by Sanofi, Inc. — Competitive Intelligence Brief. https://druglandscape.com/ci/vaxigriptetra-by-sanofi-inc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab